Inclusion Criteria:

- Patients with Ph+ and/or BCR/ABL+ ALL

- Age ≥18 years old

- De novo ALL (within 14 days from diagnosis)

- No prior treatment with any anti-leukemic drugs with the exception of steroids for no
more than 14 days (including the 7-day pretreatment already scheduled in the
protocol)

- WHO performance status ≤2

- Absence of central nervous system (CNS) leukemia

- Normal serum level of potassium, total calcium corrected for serum albumin magnesium
and phosphorus, or correctable with supplements

- ALT and AST ≤2.5 x ULN or ≤5.0 x ULN if considered due to leukemia

- Alkaline phosphatase ≤2.5 x ULN unless considered to leukemia

- Serum bilirubin ≤2 x ULN

- Serum creatinine ≤3 x ULN

- Serum amylase ≤1.5 x ULN and serum lipase ≤1.5 x ULN

- Normal cardiac function

- Written informed consent prior to any study procedures being performed.

Exclusion Criteria:

- Impaired cardiac function, including any one of the following:

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of BMS-354825 (e.g., ulcerative diseases, uncontrolled nausea,
vomiting, diarrhoea, malabsorption syndrome, or small bowel resection)

- Use of therapeutic warfarin

- Acute or chronic liver or renal disease considered unrelated to leukemia

- Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
diabetes, active or uncontrolled infection) that could cause unacceptable safety
risks or compromise compliance with the protocol

- Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF,
GM¬CSF) ≤1 week prior to starting study drug

- Patients who are currently receiving treatment with any of the medications listed in
"Appendix F" and the treatment cannot be either discontinued or switched to a
different medication prior to starting study drug. The medications listed in
"Appendix F" have the potential to prolong the QT interval.

- Patients who have received any anti-leukemic agents and treatments including steroids
for more than 14 days including 7 days pretreatment that is part of the protocol

- Patients who have received any investigational drug in the last 2 weeks

- Patients who have undergone major surgery ≤2 weeks prior to starting study drug or
who have not recovered from side effects of such therapy

- Patients who are pregnant or breast feeding, or adults of reproductive potential not
employing an effective method of birth control. (Women of childbearing potential must
have a negative serum pregnancy test within 48 hrs prior to administration of
BMS-354825). Post-menopausal women must be amenorrheic for at least 12 months to be
considered of non-childbearing potential. Male and female patients must agree to
employ an effective barrier method of birth control throughout the study and for up
to 3 months following discontinuation of study drug

- Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not
mandatory)

- Patients with a history of another primary malignancy that is currently clinically
significant or currently requires active intervention

- Non compliant to oral medication patients.